In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2. (Special Issue: Therapeutic targets and pharmacological treatment of COVID-19.)

SARS-CoV-2 has devastated the world with its rapid spread and fatality The researchers across the globe are struggling hard to search a drug to treat this infection Understanding the time constraint, the best approach is to study clinically approved drugs for control of this deadly pandemic of COVID 19 The repurposing of such drugs can be supported with the study of molecular interactions to enhance the possibility of application The present work is a molecular docking study of proteins responsible for viral propagation namely 3 Clpro, Nsp10/16, Spike protein, SARS protein receptor binding domain, Nsp 9 viral single strand binding protein and viral helicase The protein through virus enters the host cell-human angiotensin-converting enzyme 2 (ACE2) receptor, is also used as a target for molecular docking The docking was done with most discussed drugs for SARS-CoV-2 like Ritonavir, Lopinavir, Remdesivir, Chloroquine, Hydroxychloroquine (HCQ), routine antiviral drugs like Oseltamivir and Ribavirin In addition, small molecules with anti-inflammatory actions like Mycophenolic acid (MPA), Pemirolast, Isoniazid and Eriodictyol were also tested The generated data confirms the potential of Ritonavir, Lopinavir and Remdesivir as a therapeutic candidate against SARS-CoV-2 It is observed that Eriodictyol binds to almost all selected target proteins with good binding energy, suggesting its importance in treatment of COVID 19 Molecular interactions of Ritonavir, Lopinavir and Remdesivir against SARS-CoV-2 proteins enhanced their potential as a candidate drug for treatment of COVID-19 Eriodictyol had emerged as a new repurposing drug that can be used in COVID-19